Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Emerging role of ivabradine for rate control in atrial fibrillation.
Turley SL, Francis KE, Lowe DK, Cahoon WD Jr. Turley SL, et al. Among authors: francis ke. Ther Adv Cardiovasc Dis. 2016 Dec;10(6):348-352. doi: 10.1177/1753944716669658. Epub 2016 Sep 22. Ther Adv Cardiovasc Dis. 2016. PMID: 27659287 Free PMC article. Review.
Cangrelor Bridge Therapy for Gastroduodenal Biopsy.
Cahoon WD Jr, Oswalt AK, Francis KE, Magee LC, Lowe DK. Cahoon WD Jr, et al. Among authors: francis ke. J Pharm Pract. 2017 Apr;30(2):270-273. doi: 10.1177/0897190016636750. Epub 2016 Jul 8. J Pharm Pract. 2017. PMID: 27000137
Adverse events in the placebo arm of SOLO2/ENGOT-Ov21 maintenance trial of olaparib in recurrent ovarian cancer.
Francis KE, Simon S, Gebski V, Joly F, Ledermann JA, Penson RT, Oza AM, Korach J, Lainez N, Cecere SC, Tasca G, Gropp-Meier M, Fujiwara K, Lowe ES, Friedlander M, Pujade-Lauraine E, Lee CK. Francis KE, et al. Gynecol Oncol. 2024 Nov 12;192:50-55. doi: 10.1016/j.ygyno.2024.11.004. Online ahead of print. Gynecol Oncol. 2024. PMID: 39536691 Free article.
Discordance between GCIG CA-125 progression and RECIST progression in the CALYPSO trial of patients with platinum-sensitive recurrent ovarian cancer.
Zebic DS, Tjokrowidjaja A, Francis KE, Friedlander M, Gebski V, Lortholary A, Joly F, Hasenburg A, Mirza M, Denison U, Cecere SC, Ferrero A, Pujade-Lauraine E, Lee CK. Zebic DS, et al. Among authors: francis ke. Br J Cancer. 2024 Feb;130(3):425-433. doi: 10.1038/s41416-023-02528-z. Epub 2023 Dec 14. Br J Cancer. 2024. PMID: 38097739 Free PMC article.
The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer.
Francis KE, Kim SI, Friedlander M, Gebski V, Ray-Coquard I, Clamp A, Penson RT, Oza A, Perri T, Huzarski T, Martin-Lorente C, Cecere SC, Colombo N, Ataseven B, Fujiwara K, Sonke G, Vergote I, Pujade-Lauraine E, Kim JW, Lee CK. Francis KE, et al. Ann Oncol. 2022 Jun;33(6):593-601. doi: 10.1016/j.annonc.2022.02.222. Epub 2022 Feb 24. Ann Oncol. 2022. PMID: 35219776 Free article. Clinical Trial.
Reporting the trajectories of adverse events over the entire treatment course in patients with recurrent platinum-sensitive ovarian cancer treated with platinum-based combination chemotherapy regimens: A graphical approach to trial adverse event reporting.
Francis KE, Gebski V, Lord SJ, Friedlander M, Pujade-Lauraine E, Lee CK. Francis KE, et al. Eur J Cancer. 2021 May;148:251-259. doi: 10.1016/j.ejca.2021.02.006. Epub 2021 Mar 20. Eur J Cancer. 2021. PMID: 33756421 Clinical Trial.
25 results